Malaria vaccine

GPTKB entity

Statements (57)
Predicate Object
gptkbp:instance_of gptkb:vaccine
gptkbp:accessories yes
gptkbp:administered_by gptkb:children
gptkbp:approves gptkb:2021
gptkb:European_Union
gptkbp:clinical_trial over 15,000
Phase 3
gptkbp:clinical_trials_end_date gptkb:2019
gptkbp:clinical_trials_location gptkb:Africa
gptkbp:clinical_trials_start_date gptkb:2014
gptkbp:community_impact reduces malaria cases
reduces malaria deaths
gptkbp:cost_per_dose approximately $5
gptkbp:defense yes
gptkbp:developed_by gptkb:Glaxo_Smith_Kline
gptkbp:distribution gptkb:sub-Saharan_Africa
gptkbp:funding millions of dollars
https://www.w3.org/2000/01/rdf-schema#label Malaria vaccine
gptkbp:is_effective_against approximately 30%
gptkbp:is_funded_by PATH Malaria Vaccine Initiative
gptkbp:is_vulnerable_to yes
over 30 years
post-marketing surveillance
ongoing campaigns
subunit vaccine
4 doses
gptkbp:mechanism_of_action prevention of malaria infection
gptkbp:partnerships gptkb:Global_Fund
gptkb:Bill_&_Melinda_Gates_Foundation
gptkb:Gavi,_the_Vaccine_Alliance
gptkbp:public_health_importance yes
gptkbp:requires_boosters yes
gptkbp:research_institutes gptkb:University_of_Oxford
gptkb:Walter_Reed_Army_Institute_of_Research
gptkb:University_of_Ghana
gptkbp:side_effect fatigue
headache
fever
pain at injection site
gptkbp:storage refrigerated
gptkbp:target_audience children under 5
gptkbp:targets malaria
gptkbp:type RTS, S/ AS01
gptkbp:vaccine_administration_route intramuscular
gptkbp:vaccine_community_acceptance varies by region
gptkbp:vaccine_efficacy_duration up to 4 years
gptkbp:vaccine_impact_on_health_systems requires infrastructure improvements
requires training of healthcare workers
requires public education
gptkbp:vaccine_research_focus improving efficacy
reducing side effects
combination with other vaccines
expanding age range
gptkbp:vaccine_storage_temperature 2-8° C
gptkbp:whoapproval_date October 2021
gptkbp:bfsParent gptkb:Crucell
gptkbp:bfsLayer 5